JEIL PHARMACEUTICAL CO.,LTD Logo

JEIL PHARMACEUTICAL CO.,LTD

Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.

271980 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 서초구 사평대로 343 제일약품 사옥, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1959, Jeil Pharmaceutical Co., Ltd. develops, manufactures, and distributes pharmaceutical products to promote human health. The company's core activities include the production of active pharmaceutical ingredients (APIs), intermediates, and finished medicines, with a notable focus on injection-based treatments. Operating from GMP-certified facilities, Jeil Pharmaceutical's portfolio includes various therapeutic agents, such as antibiotics. The company is expanding its reach from its domestic market to a global scale, supplying its products to other nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-04 00:00
Governance Information
[기재정정]기업지배구조보고서공시
Korean 959.3 KB
2025-05-29 00:00
Governance Information
기업지배구조보고서공시
Korean 952.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.9 KB
2025-03-25 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.7 KB
2025-03-25 00:00
Board/Management Information
대표이사(대표집행임원)변경(안내공시)
Korean 5.5 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-17 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 463.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 946.6 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.5 KB
2025-02-24 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 13.8 KB

Automate Your Workflow. Get a real-time feed of all JEIL PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for JEIL PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.